Updated
Reviewed
Apr. 07, 2021

Management of Medication Toxicity or Intolerance

Gastrointestinal Effects

Table 15c. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Gastrointestinal Effects
Table 15c. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Gastrointestinal Effects
   
   
   
   

References

  1. Buck WC, Kabue MM, Kazembe PN, Kline MW. Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children. J Int AIDS Soc. 2010;13:31. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20691049.
  2. Castro JG, Chin-Beckford N. Crofelemer for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Expert Rev Clin Pharmacol. 2015;8(6):683-690. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26517110.
  3. Clay PG, Crutchley RD. Noninfectious diarrhea in HIV seropositive individuals: a review of prevalence rates, etiology, and management in the era of combination antiretroviral therapy. Infect Dis Ther. 2014;3(2):103-122. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25388760.
  4. Dikman AE, Schonfeld E, Srisarajivakul NC, Poles MA. Human immunodeficiency virus–associated diarrhea: still an issue in the era of antiretroviral therapy. Dig Dis Sci. 2015;60(8):2236-2245. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25772777.
  5. Hoffmann CJ, Fielding KL, Charalambous S, et al. Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS. 2008;22(1):67-74. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18090393.
  6. Logan C, Beadsworth MB, Beeching NJ. HIV and diarrhoea: what is new? Curr Opin Infect Dis. 2016;29(5):486-494. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27472290.
  7. Malan N, Su J, Mancini M, et al. Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study. AIDS Care. 2010;22(6):677-686. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20467943.
  8. Manfredi R, Calza L. HIV infection and the pancreas: risk factors and potential management guidelines. Int J STD AIDS. 2008;19(2):99-105. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18334062.
  9. Nachman SA, Chernoff M, Gona P, et al. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. Arch Pediatr Adolesc Med. 2009;163(2):164-171. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19188649.
  10. Oumar AA, Diallo K, Dembele JP, et al. Adverse drug reactions to antiretroviral therapy: prospective study in children in sikasso (mali). J Pediatr Pharmacol Ther. 2012;17(4):382-388. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23411444.
  11. Szoke D, Ridolfo A, Valente C, Galli M, Panteghini M. Frequency of pancreatic hyperamylasemia in human immunodeficiency virus–positive patients in the highly active antiretroviral therapy era. Am J Clin Pathol. 2016;145(1):128-133. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26712880.
  12. Tukei VJ, Asiimwe A, Maganda A, et al. Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. J Acquir Immune Defic Syndr. 2012;59(3):274-280. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22126740.
  13. Van Dyke RB, Wang L, Williams PL, Pediatric AIDS Clinical Trials Group C. Team. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. J Infect Dis. 2008;198(11):1599-1608. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19000014.
  14. Wattanutchariya N, Sirisanthana V, Oberdorfer P. Effectiveness and safety of protease inhibitor-based regimens in HIV-infected Thai children failing first-line treatment. HIV Med. 2013;14(4):226-232. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23094820.
  15. Wegzyn CM, Fredrick LM, Stubbs RO, Woodward WC, Norton M. Diarrhea associated with lopinavir/ritonavir-based therapy: results of a meta-analysis of 1469 HIV-1-infected participants. J Int Assoc Physicians AIDS Care (Chic). 2012;11(4):252-259. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22544446.

 

Management of Medication Toxicity or Intolerance

Gastrointestinal Effects

Table 15c. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Gastrointestinal Effects
Table 15c. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Gastrointestinal Effects
   
   
   
   

 

Download Guidelines